कंपनी का अवलोकन
Oragenics, Inc. (OGEN) is a development-stage biotechnology entity focused on the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases within the United States market. The company operates strictly within the healthcare sector, specifically the biotechnology industry, which implies a high-risk, high-reward environment characterized by significant investment in research before commercial product realization. As of the latest data, the company maintains a market capitalization of $2.30M and employs a workforce of 3 individuals. These figures indicate that Oragenics, Inc. is a micro-cap enterprise with negligible current revenue generation, reflecting its position as an early-stage venture where financial resources are primarily allocated to R&D activities rather than commercial scaling or profit distribution. The absence of substantial annual revenue in the traditional sense underscores that the firm's valuation is driven entirely by its intellectual property pipeline and potential future therapeutic approvals rather than current sales performance.
वित्तीय स्वास्थ्य
The financial statements reveal a Net Income (TTM) of $-9,842,487 and Free Cash Flow of $-5,746,671, while Revenue (TTM) and EBITDA are not available, indicating a pre-revenue or negligible revenue status typical of development-stage biotech firms. The substantial gap between reported revenue (N/A) and significant negative net income highlights a cost structure dominated by research and development expenditures that have not yet been offset by commercial earnings. The company holds a cash reserve of $8.40M against a debt obligation of $227,348, resulting in a Debt to Equity ratio of 2.75, which suggests a balance sheet that is technically leveraged but supported by significant liquid assets. Despite the high debt-to-equity figure, the Current Ratio stands at 5.64, indicating robust short-term liquidity where current assets significantly exceed current liabilities. The margins across the board—Gross Margin, Operating Margin, and Profit Margin—are all recorded at 0.0%, which is consistent with a company that has not yet achieved commercial profitability or generated measurable sales volume. Return on Equity is reported at -243.9% and Return on Assets at -101.4%, metrics that reflect the capital-intensive nature of the business where accumulated losses have eroded shareholder equity and total asset value relative to book value.
मूल्यांकन आकलन
The P/E Ratio (TTM) is listed as N/A due to the lack of positive earnings, while the Forward P/E is -0.05, a metric that technically implies earnings are negative and traditional price-to-earnings multiples are inapplicable for valuation purposes. The Price to Book ratio is 0.27, indicating that the market values the company at a fraction of its book value, a common characteristic for distressed or pre-profitability biotechnology assets where asset value does not yet reflect future pipeline potential. Alternative valuation metrics such as Price to Sales and EV/EBITDA are also N/A, suggesting that standard valuation multiples cannot be applied until the company generates revenue and operating cash flows. The stock has exhibited extreme volatility over the past year, trading between a 52-Week High of $9.60 and a 52-Week Low of $0.52. Given the low price relative to the historical high, the current trading price sits significantly below the 52-week peak, reflecting the market's cautious stance on the company's near-term commercial prospects. The Beta is 1.11, meaning the stock price is approximately 11% more volatile than the broader market, exposing investors to higher systematic risk than large-cap healthcare equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet established a consistent track record of commercial sales or reported earnings growth. Since the company does not pay dividends, there is no Dividend Yield or Payout Ratio to evaluate, and the Payout Ratio is effectively 0.0%. Consequently, the company reinvests all available resources, including its $8.40M cash balance, directly into research and development to advance its lead product, ONP-002, rather than distributing income to shareholders. The overall growth and income profile for Oragenics, Inc. is currently defined by capital preservation and asset accumulation rather than income generation or expansion through organic sales growth. This strategic focus is typical for development-stage biotechs where survival and regulatory approval of the neurosteroid pipeline are the primary objectives before any income-based growth can be realized.